Evidence map›Paper›PMID 34691080›Full record

ArticleFrontiers in immunology2021

TNF-α Carried by Plasma Extracellular Vesicles Predicts Knee Osteoarthritis Progression.

Xin Zhang, Ming-Feng Hsueh, Janet L Huebner, Virginia B Kraus

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. CSPG4Osteoarthritis and cartilage open · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xin ZhangDuke Molecular Physiology Institute, Duke University School of Medicine, Duke University, Durham, NC, United States.
Ming-Feng HsuehDuke Molecular Physiology Institute, Duke University School of Medicine, Duke University, Durham, NC, United States.
Janet L HuebnerDuke Molecular Physiology Institute, Duke University School of Medicine, Duke University, Durham, NC, United States.
Virginia B KrausDuke Molecular Physiology Institute, Duke University School of Medicine, Duke University, Durham, NC, United States.
Duke University · US

Funding

Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI Virginia B Kraus · 2006 to 2026
$24.6M
Extracellular Vesicle Analyses to Develop Aging and Resilience BiomarkersR01AG070146 · NIA · DUKE UNIVERSITY · PI KRAUS, VIRGINIA B · 2021 to 2025
$3.1M
Extracellular Vesicles and Their Role in Hallmarks of AgingR56AG060895 · NIA · DUKE UNIVERSITY · PI KRAUS, VIRGINIA · 2018 to 2018
$659k
NIA NIH HHS P30 AG028716NIA NIH HHS R01 AG070146NIA NIH HHS R56 AG060895
6 · The paper itself

Abstract

Objectives: To identify plasma extracellular vesicles (EVs) associated with radiographic knee osteoarthritis (OA) progression. Methods: EVs of small (SEV), medium (MEV) and large (LEV) sizes from plasma of OA participants (n=30) and healthy controls (HCs, n=22) were profiled for surface markers and cytokine cargo by high-resolution flow cytometry. The concentrations of cytokines within (endo-) and outside (exo-) EVs were quantified by multiplex ELISA. EV associations with knee radiographic OA (rOA) progression were assessed by multivariable linear regression (adjusted for baseline clinical variables of age, gender, BMI and OA severity) and receiver operating characteristic (ROC) curve analysis. Results: Based on integrated mean fluorescence intensity (iMFI), baseline plasma MEVs carrying CD56 (corresponding to natural killer cells) predicted rOA progression with highest area under the ROC curve (AUC) 0.714 among surface markers. Baseline iMFI of TNF-α in LEVs, MEVs and SEVs, and the total endo-EV TNF-α concentration, predicted rOA progression with AUCs 0.688, 0.821, 0.821, 0.665, respectively. In contrast, baseline plasma exo-EV TNF-α (the concentration in the same unit of plasma after EV depletion) did not predict rOA progression (AUC 0.478). Baseline endo-EV IFN-γ and exo-EV IL-6 concentrations were also associated with rOA progression, but had low discriminant capacity (AUCs 0.558 and 0.518, respectively). Conclusions: Plasma EVs carry pro-inflammatory cargo that predict risk of knee rOA progression. These findings suggest that EV-associated TNF-α may be pathogenic in OA. The sequestration of pathogenic TNF-α within EVs may provide an explanation for the lack of success of systemic TNF-α inhibitors in OA trials to date.

Indexed as

AgedExtracellular VesiclesFemaleHumansMaleMiddle AgedOsteoarthritis, KneeTumor Necrosis Factor-alphaTumor Necrosis Factor-alphacytokinesextracellular vesiclesimmune cellsknee osteoarthritis progressionTNF-α

Identifiers

PMID34691080
PMCPMC8526961
OpenAlexW3202007934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.